MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer
The primary objectives of this study are to compare MK-2870 to Treatment of Physician’s Choice (TPC) with respect to progression-free survival (PFS) per response evaluation criteria in solid tumors (RECIST 1.1),